The FDA released a draft guidance to help sponsors in the clinical development of drugs for the treatment of gastroesophageal reflux disease in pediatric patients. The draft discusses clinical presentation by age and disease, study populations, endpoints and pharmacometric issues affecting dosing, according to a notice slated for publication in Friday's Federal Register. Comments are due in 60 days.